A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Provision of consent ECOG performance status 0-2 Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML) Must have previously received standard therapy Adequate organ function
Exclusion Criteria:
Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment Patients should discontinue statins prior to starting study treatment CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy) Any evidence of severe or uncontrolled systemic diseases Any known uncontrolled inter-current illness QTcF prolongation (> 480 msec)
